Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab +/- chemotherapy in neoadjuvant HNSCC
NCT04164238Phase 2Unknown
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Nov 2019
- Primary completion
- Nov 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in head and neck squamous cell carcinoma (HNSCC), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Status: unknown.
02
Drugs
toripalimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04164238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04164238.